维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

5篇 您的检索式：作者名="Pingfu Fu"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer显示文摘	Neelesh Sharma Nathan Pennell Myles Nickolich Balazs Halmos Patrick Ma Tarek Mekhail Pingfu Fu Afshin Dowlati	2014	Investigational New Drugs2014，，2：	2
	2	Apigenin attenuates insulin-like growth factor-1 signaling in an autochthonous nouse prostate cancer model显示文摘	Shukla S MacLennan G T Fu Pingfu		0，，：	1
	3	Deregulation of FOXO3A during prostate cancer progression显示文摘	Sanjeev Shukla Meenakshi Shukla Gregory MacLennan Pingfu Fu Sanjay Gupta	2009	International Journal of Oncology2009，，6：	1
	4	MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer显示文摘	Alan Siroy Fadi W. Abdul-Karim John Miedler Nancy Fong Pingfu Fu Hannah Gilmore Joseph Baar	2013	Human Pathology2013，，：	1
	5	Survival in men older than 75 years with low- and intermediate-grade prostate cancer managed with watchful waiting with active surveillance显示文摘Objective:Recent studies have reported the underuse of active surveillance or watchful wait-ing for low-risk prostate cancer in the United States.This study examined prostate cancer-specific and all-cause death in elderly patients older than 75 years with low-risk tumors managed with active treatment versus watchful waiting with active surveillance(WWAS).Methods:We performed survival analysis in a cohort of 18,599 men with low-risk tumors(early and localized tumors)who were 75 years or older at the time of prostate cancer diagnosis in the linked Surveillance,Epidemiology,and End Results(SEER)-Medicare database(from 1992 to 1998)and who were followed up through December 2003.WWAS was defined as having an-nual screening for prostate-specific antigen and/or digital rectal examination during the follow-up period.The risks of prostate cancer-specific and all-cause death were compared by Cox regression models.The propensity score matching technique was used to address potential selection bias.Results:In patients with well-differentiated(Gleason score 2-4)and localized disease,those managed with WWAS without delayed treatment had higher risk of all-cause death(hazard ratio 1.20,95%confidence interval 1.13-1.28)but a substantially lower risk of prostate cancer-specific death(hazard ratio 0.62,confidence interval 0.51-0.75)than patients undergoing active treatment.Patients managed with WWAS with delayed treatment had comparable mortality outcomes.Sensi-tivity analyses based on propensity score matching yielded similar results.Conclusion:In men older than 75 years with well-differentiated and localized prostate cancer,WWAS without delayed treatment had a lower risk of prostate cancer-specific death and compa-rable all-cause death as compared with active treatment.Those patients in whom treatment was delayed had comparable mortality outcomes.Our results support WWAS as an initial management option for older men with well-differentiated and localized prostate cancer.	Tzuyung D.Kou Siran M.Koroukian Pingfu Fu Derek Raghavan Gregory S.Cooper Li Li	2015	Family Medicine and Community Health2015，3，3：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费